TY - JOUR
T1 - Chronic Kidney Disease and Coronary Artery Disease
T2 - JACC State-of-the-Art Review
AU - Conference Participants
AU - Sarnak, Mark J.
AU - Amann, Kerstin
AU - Bangalore, Sripal
AU - Cavalcante, João L.
AU - Charytan, David M.
AU - Craig, Jonathan C.
AU - Gill, John S.
AU - Hlatky, Mark A.
AU - Jardine, Alan G.
AU - Landmesser, Ulf
AU - Newby, L. Kristin
AU - Herzog, Charles A.
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Marwick, Thomas H.
AU - Banerjee, Debasish
AU - Briguori, Carlo
AU - Chang, Tara I.
AU - Chen, Chien Liang
AU - deFilippi, Christopher R.
AU - Ding, Xiaoqiang
AU - Ferro, Charles J.
AU - Gill, Jagbir
AU - Gössl, Mario
AU - Isbel, Nicole M.
AU - Ishii, Hideki
AU - Jardine, Meg J.
AU - Kalra, Philip A.
AU - Laufer, Günther
AU - Lentine, Krista L.
AU - Lobdell, Kevin
AU - Lok, Charmaine E.
AU - London, Gérard M.
AU - Małyszko, Jolanta
AU - Mark, Patrick B.
AU - Marwan, Mohamed
AU - Nie, Yuxin
AU - Parfrey, Patrick S.
AU - Pecoits-Filho, Roberto
AU - Pilmore, Helen
AU - Qunibi, Wajeh Y.
AU - Raggi, Paolo
AU - Rattazzi, Marcello
AU - Rossignol, Patrick
AU - Ruturi, Josiah
AU - Sabanayagam, Charumathi
AU - Shanahan, Catherine M.
AU - Shroff, Gautam R.
AU - Shroff, Rukshana
N1 - Funding Information:
The conference was sponsored by Kidney Disease: Improving Global Outcomes and was supported in part by unrestricted educational grants from Akebia Therapeutics, Amgen, Boehringer Ingelheim, Corvidia, Daiichi-Sankyo, Fresenius Medical Care, Kyowa Kirin, and Suntop Healthcare Corp. Dr. Sarnak has served on the Steering Committee of Akebia; has received consulting fees paid to his institution from Akebia; and has served on the Advisory Board of Bayer. Dr. Bangalore has received consultant or advisory grants from Abbott Vascular, Amgen, Biotronik, Pfizer, and Reata. Dr. Cavalcante has had consultant relationships with Abbott Vascular and Boston Scientific; and has received research grant support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, and Siemens. Dr. Charytan has had consultant relationships with Allena, Amgen, AstraZeneca, Daiichi-Sankyo, Fresenius, Janssen, Medtronic/Corvidien, Merck, Novo Nordisk, and Zoll Medical; has received honoraria from Fresenius; and has received research grants from Medtronic and the National Institutes of Health (NIH). Dr. Hlatky has served as a Clinical Event Adjudicator for Tricida. Dr. Landmesser has received honoraria from Amgen, Bayer, The Medicines Company, and Sanofi. Dr. Newby has received consulting fees from Biokier and Roche Diagnostics; has served on the Advisory Boards of Metanomics and Ortho Clinical Diagnostics; and has received research grants paid to her institution from Amylin and Boehringer Ingelheim. Dr. Herzog has received consulting fees from AbbVie, Amgen, AstraZeneca, Corvidia, DiaMedica, FibroGen, Janssen, Oxford University, OxThera, Pfizer, and Relypsa; has stock equity in Boston Scientific, General Electric, Johnson & Johnson, and Merck; has received research grants from Amgen, Bristol-Myers Squibb, National Institute of Diabetes and Digestive and Kidney Diseases/NIH, National Heart, Lung, and Blood Institute/NIH, Relypsa, and the University of British Columbia; has received honoraria from the American College of Cardiology; and has received author royalties from UpToDate. Dr. Wheeler has received consulting fees from Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Janssen, Napp/Mundipharma, and Vifor Fresenius Medical Care Renal Pharma; and has received honoraria from Astellas, Boehringer Ingelheim, Janssen, Mitsubishi Tanabe, Ono Pharmaceutical, and Pharmacosmos. Dr. Winkelmayer has received consulting fees and honoraria from Akebia/Otsuka, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and Vifor Fresenius Medical Care Renal Pharma. Dr. Marwick has received research grants from GE Medical Systems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Steven Weisbord, MD, MSc, served as Guest Associate Editor for this paper.
PY - 2019/10/8
Y1 - 2019/10/8
N2 - Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research.
AB - Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research.
UR - http://www.scopus.com/inward/record.url?scp=85072526119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072526119&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.08.1017
DO - 10.1016/j.jacc.2019.08.1017
M3 - Review article
C2 - 31582143
AN - SCOPUS:85072526119
VL - 74
SP - 1823
EP - 1838
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
SN - 0735-1097
IS - 14
ER -